Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia

By Boyle P.   Robertson C.   Manski R.   Padley R.J.   Roehrborn C.G.  

Urology, Vol. 58, Iss. 5, 2001-11 ,pp. : 717-722

Elsevier

Access to resources Recommend Favorite

Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia

By Boyle P.   Robertson C.   Lowe F.   Roehrborn C.  

Urology, Vol. 55, Iss. 4, 2000-04 ,pp. : 533-539

Elsevier

Access to resources Recommend Favorite

Long-term evaluation of Transurethral Needle Ablation of the prostate (TUNA) for treatment of benign prostatic hyperplasia (BPH): clinical outcome after 5 years

By Zlotta A.   Schulman C.   Giannakopoulos X.   Machlum H.   Ostrem E.  

European Urology Supplements, Vol. 1, Iss. 1, 2002-01 ,pp. : 129-129

Elsevier

Access to resources Recommend Favorite

Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia

By Lowe F.C.   McDaniel R.L.   Chmiel J.J.   Hillman A.L.  

Urology, Vol. 46, Iss. 4, 1995-10 ,pp. : 477-483

Elsevier

Access to resources Recommend Favorite

Clinical outcome at 3 months after transurethral vaporization of prostate for benign prostatic hyperplasia

By Chen S.-S.   Chiu A.W.   Lin A.T.L.   Chen K.-K.   Chang L.S.  

Urology, Vol. 50, Iss. 2, 1997-08 ,pp. : 235-238

Elsevier

Access to resources Recommend Favorite